Association between BRAF V600E and NRAS Q61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma

Cancer Causes and Control

Volumn 25, Issue 10, 2014, Pages 1379-1386

  Wu, Shaowei ^a,b   Kuo, Helen ^a   Li, Wen Qing ^b   Canales, Alvaro Laga ^a   Han, Jiali ^a,c   Qureshi, Abrar A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROWN UNIVERSITY   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

BRAF; Melanoma; NRAS; Sun exposure; Survival

Indexed keywords

B RAF KINASE; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER RISK; CANCER SPECIFIC SURVIVAL; CARCINOGENESIS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE ACTIVITY; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MOLECULAR PATHOLOGY; NRAS GENE; ONCOGENE; OUTCOME ASSESSMENT; PYROSEQUENCING; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; VERY ELDERLY; ADVERSE EFFECTS; ENVIRONMENTAL EXPOSURE; FOLLOW UP; GENETICS; MELANOMA; MORTALITY; MUTATION; ODDS RATIO; PROGNOSIS; PROSPECTIVE STUDY; SKIN NEOPLASMS; TREATMENT OUTCOME; ULTRAVIOLET RADIATION;

ADULT; AGED; AGED, 80 AND OVER; ENVIRONMENTAL EXPOSURE; FEMALE; FOLLOW-UP STUDIES; GTP PHOSPHOHYDROLASES; HUMANS; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; ODDS RATIO; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; RISK FACTORS; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; ULTRAVIOLET RAYS;

EID: 84911001375     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-014-0443-x     Document Type: Article

References (37)

1. Geller AC, Miller DR, Annas GD et al (2002) Melanoma incidence and mortality among US whites, 1969–1999. JAMA 288:1719–1720
2. Jemal A, Devesa SS, Hartge P et al (2001) Recent trends in cutaneous melanoma incidence among Whites in the United States. J Natl Cancer Inst 93:678–683
3. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
4. Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41:28–44
5. Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 41:2040–2059
6. Hacker E, Hayward NK, Dumenil T et al (2010) The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. J Invest Dermatol 130(1):241–248
7. Qureshi AA, Zhang M, Han J (2011) Heterogeneity in host risk factors for incident melanoma and non-melanoma skin cancer in a cohort of US women. J Epidemiol 21(3):197–203
8. Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 41:45–60
9. Whiteman DC, Watt P, Purdie DM et al (2003) Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 95:806–812
10. Whiteman DC, Stickley M, Watt P et al (2006) Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 24:3172–3177
11. Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147
12. Landi MT, Bauer J, Pfeiffer RM et al (2006) MC1R germline variants confer risk for BRAF -mutant melanoma. Science 313:521–522
13. Maldonado JL, Fridlyand J, Patel H et al (2003) Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95:1878–1890
14. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954
15. Goydos JS, MannB Kim HJ et al (2005) Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 200:362–370
16. van Elsas A, Zerp SF, van der Flier S et al (1996) Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 149:883–893
17. Ellerhorst JA, Greene VR, Ekmekcioglu S et al (2011) Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17(2):229–235
18. Campbell PM, Der CJ (2004) Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 14:105–114
19. Meier F, Schittek B, Busch S et al (2005) The RAS/RAF/MEK/ERK and PI3 K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 10:2986–3001
20. Kudchadkar RR, Smalley KS, Glass LF et al (2013) Targeted therapy in melanoma. Clin Dermatol 31(2):200–208
21. Edlundh-Rose E, Egyhazi S, Omholt K et al (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16:471–478
22. Autier P, Doré JF (1998) Influence of sun exposures during childhood and during adulthood on melanoma risk. EPIMEL and EORTC Melanoma Cooperative Group. European Organisation for Research and Treatment of Cancer. Int J Cancer 77(4):533–537
23. Qureshi AA, Laden F, Colditz GA et al (2008) Geographic variation and risk of skin cancer in US women. Differences between melanoma, squamous cell carcinoma, and basal cell carcinoma. Arch Intern Med 168(5):501–507
24. Whiteman DC, Whiteman CA, Green AC (2001) Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 12:69–82
25. Lee JH, Choi JW, Kim YS (2011) Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164(4):776–784
26. Thomas NE, Edmiston SN, Alexander A et al (2007) Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 16:991–997
27. Venesio T, Chiorino G, Balsamo A et al (2008) In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation. Mod Pathol 21:716–726
28. Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R et al (2007) Distinct clinical and pathological features are associated with the BRAF (T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 127(4):900–905
29. Thomas NE, Berwick M, Cordeiro-Stone M (2006) Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation? J Invest Dermatol 126:1693–1696
30. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ (2005) Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol 36(5):486–493
31. Poynter JN, Elder JT, Fullen DR et al (2006) BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16(4):267–273
32. Long GV, Menzies AM, Nagrial AM et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29(10):1239–1246
33. Devitt B, Liu W, Salemi R et al (2011) Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 24(4):666–672
34. Akslen LA, Angelini S, Straume O et al (2005) BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 125:312–317
35. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516
36. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107–114
37. Sivertsson A, Platz A, Hansson J, Lundeberg J (2002) Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastases. Clin Chem 48:2164–2170